Avanir Pharmaceuticals News
Most Popular Avanir Pharmaceuticals Story
Avanir stock boosted by promising Zenvia data
A Phase III trial of Avanir Pharmaceuticals' closely-watched drug Zenvia showed that the drug relieved Pseudobulbar affect (PBA) in a subset of multiple sclerosis patients, sending Avanir's stock up... Read more...
Latest Headlines
- November 10, 2009
- October 9, 2009
- October 7, 2009
- August 11, 2009
- March 27, 2008
- November 9, 2006
- October 30, 2006
- August 8, 2006
- May 24, 2006
- May 22, 2006
- May 9, 2006
- September 21, 2005
- July 10, 2005
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
